Unique ID issued by UMIN | UMIN000010940 |
---|---|
Receipt number | R000012806 |
Scientific Title | The comparison of azilsartan and amlodipine for treatment of VEGF receptor-tyrosine kinase inhibitor-induced hypertension in advanced kidney cancer patients |
Date of disclosure of the study information | 2013/06/12 |
Last modified on | 2018/06/18 17:20:23 |
The comparison of azilsartan and amlodipine for treatment of VEGF receptor-tyrosine kinase inhibitor-induced hypertension in advanced kidney cancer patients
The comparison of azilsartan and amlodipine for treatment of VEGFR-TKI-induced hypertension
The comparison of azilsartan and amlodipine for treatment of VEGF receptor-tyrosine kinase inhibitor-induced hypertension in advanced kidney cancer patients
The comparison of azilsartan and amlodipine for treatment of VEGFR-TKI-induced hypertension
Japan |
VEGFR-TKI-induced hypertension
Hematology and clinical oncology | Urology |
Malignancy
NO
Vascular endothelial growth factor receptor tyrosin kinase inhibitors (VEGFR-TKI) have high incidence of hypertension as an adverse event, and this hypertension becomes a critical factor of discontinuation of VEGFR-TKI. Therefore, the control of hypertension is very important for continuation of VEGFR-TKI and to achieve the best outcome in kidney cancer treatment. In this study, we will compare the efficacy of azilsartan and amlodipine as a treatment for VEGFR-TKI-induced hyprtension.
Efficacy
The comparison of the efficacy between azilsartan group and amlodipine group
Interventional
Parallel
Randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
Azilsartan
amlodipine
20 | years-old | <= |
Not applicable |
Male and Female
1. pathologically diagnosed as cancer or sarcoma
2. no aplication for radical treatment because of locally advanced or metastatic disease
3. patients know their diagnosis and status
4. undergoing VEGFR-TKI treatment
5. without hypertension at the start of VEGFR-TKI
6. without anti-hypertensive at the start of VEGFR-TKI
7. newly arisen hypertension (systolic >140mmHg and increase 20mmHg starting VEGFR-TKI compared with before VEGFR-TKI treatment
8. obtained informed concent by document
1. < 20 year-old
2. Cr>3.0mg/dl or eGFR<15ml/min
3. bilateral renal arterial stenosis or unilateral renal rterial stenosis in solitary kidney
4. allergy to angiotensin 2 receptor blockers or calcium channel blockers
and patients who were thought as inadequate for this study by doctor in charge
10
1st name | |
Middle name | |
Last name | Kouji Izumi |
Kanazawa University
Department of Urology
13-1 Takaramachi, Kanazawa
076-265-2393
azuizu2003@yahoo.co.jp
1st name | |
Middle name | |
Last name | Izumi, Kouji |
Kanazawa University
Department of Urology
13-1 Takaramachi, Kanazawa, Japan
076-265-2393
azuizu2003@yahoo.co.jp
Kanazawa University, 13-1 Takaramachi, Kanazawa
none
Self funding
NO
2013 | Year | 06 | Month | 12 | Day |
Unpublished
No longer recruiting
2013 | Year | 06 | Month | 12 | Day |
2013 | Year | 06 | Month | 12 | Day |
2013 | Year | 06 | Month | 12 | Day |
2018 | Year | 06 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012806
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |